Marshall Wace, LLP 2seventy Bio, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 443,615 shares of TSVT stock, worth $1.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
443,615
Previous 1,110,019
60.04%
Holding current value
$1.88 Million
Previous $4.74 Million
49.93%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding TSVT
# of Institutions
128Shares Held
47.8MCall Options Held
84.3KPut Options Held
53.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$25.2 Million3.34% of portfolio
-
Morgan Stanley New York, NY4.36MShares$18.4 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$17.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.91MShares$16.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.73MShares$15.8 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $160M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...